Please assess the completion status of the following clinical trial:

Trial Title: Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* 6-20 Grade 1/2 AKs on the face or scalp~* a history of AK therapy within the treatment area at least twice in the two years prior to study entry~Exclusion Criteria:~* Pregnancy~* Grade 3 AKs or atypical AKs (e.g., AK \> 1 cm2 in size) within the Treatment Area~* lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the Treatment Area~* plans to be exposed to artificial tanning devices or excessive sunlight during the trial~* Subject is immunosuppressed~* unsuccessful outcome from previous ALA-PDT therapy~* history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis~* skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy~* skin pathology or condition that could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy~* any condition which would make it unsafe for the subject to participate in this research study~* currently enrolled in an investigational drug or device study~* has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment~* known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)~* Subject has;~  * an active herpes simplex infection OR~ * a history of 2 or more outbreaks within the past 12 months, in the Treatment Area~* use of the following topical preparations on the extremities to be treated:~  * Keratolytics including urea (greater than 5%), alpha hydroxyacids \[e.g.glycolic acid, lactic acid, etc. greater than 5%\], salicylic acid (greater than 2%) within 2 days of initiation of treatment.~ * Cryotherapy within 2 weeks of initiation of treatment~ * Retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of initiation of treatment.~ * Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, imiquimod or other topical treatments for AK within 8 weeks of initiation of treatment.~ * Two or more ALA PDT treatments in the past 6 months~* use of systemic retinoid therapy within 6 months of initiation of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Broad Area ALA 1-hour incubation (Type: EXPERIMENTAL): Broad Area ALA 1-hour incubation
- Broad Area ALA 2-hour incubation (Type: EXPERIMENTAL): Broad Area ALA 2-hour incubation
- Broad Area ALA 3-hour incubation (Type: EXPERIMENTAL): Broad Area ALA 3-hour incubation
- Spot ALA 2-hour incubation (Type: EXPERIMENTAL): Spot ALA 2-hour incubation
- Vehicle PDT (Type: PLACEBO_COMPARATOR): VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).